GATTI, GIULIANA
 Distribuzione geografica
Continente #
NA - Nord America 1.120
EU - Europa 888
AS - Asia 546
AF - Africa 2
OC - Oceania 2
SA - Sud America 1
Totale 2.559
Nazione #
US - Stati Uniti d'America 1.113
CN - Cina 530
IE - Irlanda 330
UA - Ucraina 150
FI - Finlandia 122
DE - Germania 92
SE - Svezia 77
IT - Italia 47
GB - Regno Unito 41
BE - Belgio 17
IN - India 10
CA - Canada 7
FR - Francia 6
PL - Polonia 3
AU - Australia 2
KR - Corea 2
MU - Mauritius 2
RU - Federazione Russa 2
CL - Cile 1
ID - Indonesia 1
JP - Giappone 1
NL - Olanda 1
TH - Thailandia 1
TR - Turchia 1
Totale 2.559
Città #
Dublin 330
Chandler 278
Jacksonville 201
Nanjing 158
Ann Arbor 82
Beijing 82
Ashburn 61
Princeton 52
Lawrence 50
Nanchang 49
Changsha 48
Wilmington 45
Shenyang 39
Hebei 33
Jiaxing 31
Helsinki 30
Tianjin 29
Medford 28
Boardman 24
Woodbridge 23
Brussels 17
Hangzhou 17
Shanghai 17
Houston 9
Pavia 9
Milan 8
Pune 7
Toronto 6
Verona 6
Fairfield 5
Norwalk 5
Zhengzhou 5
Des Moines 4
Seattle 4
Taizhou 4
Berlin 3
Cologno Monzese 3
Guangzhou 3
Palermo 3
Radomsko 3
San Francisco 3
Auburn Hills 2
Bergamo 2
Catania 2
Como 2
Kunming 2
London 2
Los Angeles 2
Tappahannock 2
Bangkok 1
Briga Novarese 1
Carovigno 1
Changchun 1
Dearborn 1
Falkenstein 1
Huntington 1
Ipswich 1
Markham 1
Melbourne 1
New Delhi 1
Ningbo 1
Rome 1
Rowville 1
Stanton 1
Tokyo 1
Voghera 1
Walnut 1
Totale 1.848
Nome #
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbamazepine in healthy women 94
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. 82
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. 77
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. 76
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine sources of variability and preliminary observations on relations with clinical response. 71
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma 70
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. 69
A simple and rapid HPLC-UV method for the determination of retigabine in human plasma 69
A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers 64
The new antiepileptic drugs: Pharmacological and clinical aspects. 63
Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. 63
Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 62
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 61
Farmacocinetica delle benzodiazepine. 61
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. 60
Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response 59
Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers 57
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. 55
The disposition of theophylline in patients with lung and breast cancer. 55
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography 54
Clinical pharmacokinetics of fluvoxamine. 53
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.SOPHIE Study Group. 53
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. 53
Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. 52
Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. 52
The Influence of Dosage, Age, and Comedication on Steady State Plasma Lamotrigine Concentrations in Epileptic Children 51
A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy 50
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy 50
Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers. 50
CYP2D6-related oxidation polymorphism in Italy 50
Protective effect of cyanidin (IdB 1027) against aspirin-induced fall in gastric transmucosal potential difference in normal subjects. 49
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. 49
A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. 49
Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. 47
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. 46
Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. 45
Challenges in the pharmacotherapy of the epilepsies 44
Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. 42
DIFFERENTIAL-EFFECTS OF VALPROIC ACID AND ENZYME-INDUCING ANTICONVULSANTS ON NIMODIPINE PHARMACOKINETICS IN EPILEPTIC PATIENTS 41
Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy 40
The Influence of Ethnic Factors and Gender on CYP1A2-Mediated Drug Disposition: A Comparative Study in Caucasian and Chinese Subjects Using Phenacetin as a Marker Substrate 38
Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. 37
Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial 36
Reduced Plasma Nisoldipine Concentrations in Phenytoin-Treated Patients with Epilepsy 34
Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers 33
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy 32
The disposition of primidone in elderly patients. 30
The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. 29
Possible enhancement of the first-pass metabolism of prenacetin by grape juice in Chinese subjects 24
Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy 24
Totale 2.605
Categoria #
all - tutte 8.444
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.444


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 6 3 3
2019/2020659 188 230 4 34 4 30 5 34 5 68 48 9
2020/2021318 32 27 13 28 1 39 5 51 13 50 40 19
2021/2022210 10 2 4 7 2 6 5 12 13 8 37 104
2022/2023849 91 74 7 53 76 81 0 57 374 4 19 13
2023/2024216 46 40 5 19 25 50 4 23 3 1 0 0
Totale 2.605